---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-013692"
form_type: "8-K"
ticker: "ABBV"
cik: "0001551152"
company_name: "AbbVie Inc."
filed_at: "2024-02-12T23:59:59+00:00"
generated_at: "2026-06-06T04:17:48.324151+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AbbVie completes $31.26/share ImmunoGen acquisition; reaffirms FY2024 EPS guidance with $0.42 dilution

## Summary
- Acquired all outstanding ImmunoGen shares for $31.26 each; ImmunoGen ceases trading on NASDAQ.
- Adds ELAHERE (FRα-positive ovarian cancer ADC) and pipeline assets including IMGN-151 and pivekimab sunirine.
- Reaffirms full-year 2024 adjusted diluted EPS guidance of $11.05-$11.25, now including $0.42 dilution from ImmunoGen and pending Cerevel.
- Updates Q1 2024 adjusted EPS guidance to $2.26-$2.30 from $2.30-$2.34 due to $0.04 dilutive impact from ImmunoGen.
- Expects the acquisition to be accretive to diluted EPS beginning in 2027 and significantly accretive over long term.

## SEC filing metadata
- accession: 0001104659-24-013692
- form_type: 8-K
- ticker: ABBV
- cik: 0001551152
- company_name: AbbVie Inc.
- filed_at: 2024-02-12T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551152/000110465924013692/0001104659-24-013692-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551152/000110465924013692/tm245657d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-013692
- JSON: https://secwatch.observer/filing/0001104659-24-013692.json
- Plain text: https://secwatch.observer/filing/0001104659-24-013692.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.